Content area

Abstract

Interleukin (IL)-10 is a contributing factor to neuroprotection of mesenchymal stem cell (MSC) transplantation after ischemic stroke. Our aim was to increase therapeutic effects by combining MSCs and ex vivo IL-10 gene transfer with an adeno-associated virus (AAV) vector using a rat transient middle cerebral artery occlusion (MCAO) model. Sprague-Dawley rats underwent 90 min MCAO followed by intravenous administration of MSCs alone or IL-10 gene-transferred MSCs (MSC/IL-10) at 0 or 3 hr after ischemia reperfusion. Infarct lesions, neurological deficits, and immunological analyses were performed within 7 days after MCAO. 0-hr transplantation of MSCs alone and MSC/IL-10 significantly reduced infarct volumes and improved motor function. Conversely, 3-hr transplantation of MSC/IL-10, but not MSCs alone, significantly reduced infarct volumes (p < 0.01) and improved motor function (p < 0.01) compared with vehicle groups at 72 hr and 7 days after MCAO. Immunological analysis showed that MSC/IL-10 transplantation significantly inhibits microglial activation and pro-inflammatory cytokine expression compared with MSCs alone. Moreover, overexpressing IL-10 suppressed neuronal degeneration and improved survival of engrafted MSCs in the ischemic hemisphere. These results suggest that overexpressing IL-10 enhances the neuroprotective effects of MSC transplantation by anti-inflammatory modulation and thereby supports neuronal survival during the acute ischemic phase.

Details

Title
Mesenchymal Stem Cells Overexpressing Interleukin-10 Promote Neuroprotection in Experimental Acute Ischemic Stroke
Author
Nakajima, Masataka 1 ; Nito, Chikako 2 ; Sowa, Kota 1 ; Suda, Satoshi 2 ; Nishiyama, Yasuhiro 2 ; Nakamura-Takahashi, Aki 3 ; Nitahara-Kasahara, Yuko 4 ; Imagawa, Kiwamu 5 ; Hirato, Tohru 5 ; Ueda, Masayuki 2 ; Kimura, Kazumi 2 ; Okada, Takashi 4 

 Department of Neurological Science, Graduate School of Medicine, Nippon Medical School, Tokyo 113-8603, Japan; Department of Biochemistry and Molecular Biology, Graduate School of Medicine, Nippon Medical School, Tokyo 113-8603, Japan 
 Department of Neurological Science, Graduate School of Medicine, Nippon Medical School, Tokyo 113-8603, Japan 
 Department of Biochemistry and Molecular Biology, Graduate School of Medicine, Nippon Medical School, Tokyo 113-8603, Japan; Department of Pharmacology, Tokyo Dental College, Tokyo 101-0061, Japan 
 Department of Biochemistry and Molecular Biology, Graduate School of Medicine, Nippon Medical School, Tokyo 113-8603, Japan; Department of Cell and Gene Therapy, Graduate School of Medicine, Nippon Medical School, Tokyo 113-8603, Japan 
 JCR Pharmaceuticals Co., Ltd., Hyogo, 659-0021, Japan 
Pages
102-111
Section
Original Article
Publication year
2017
Publication date
Sep 15, 2017
Publisher
Elsevier Limited
e-ISSN
23290501
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2307590042
Copyright
©2017. The Author(s)